biperiden has been researched along with Idiopathic Parkinson Disease in 46 studies
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.
Excerpt | Relevance | Reference |
---|---|---|
"In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy." | 7.65 | Visual hallucinations and delirium during treatment with amantadine (Symmetrel). ( Postma, JU; Van Tilburg, W, 1975) |
"Bromocriptine (10mg/day) was the second dopaminergic therapy employed in the present work." | 5.28 | [L-dopa, biperiden and sebum excretion in Parkinson disease]. ( Villares, JC, 1989) |
"We investigated the effect of an anticholinergic (biperiden) and a dopamine agonist (apomorphine) on tremor, rigidity, and akinesia in patients with idiopathic Parkinson's disease." | 5.09 | Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. ( Poewe, W; Schelosky, L; Scholz, U; Schrag, A, 1999) |
"We found that levodopa had a good effect on the amplitude of the resting tremor, while the effect of biperiden was weaker." | 5.09 | A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor. ( Milanov, I, 2001) |
"In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy." | 3.65 | Visual hallucinations and delirium during treatment with amantadine (Symmetrel). ( Postma, JU; Van Tilburg, W, 1975) |
"This outnumbered sales to patients with Parkinson's disease by >20 to 1." | 1.35 | The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. ( Bramness, JG; Gjerden, P; Slørdal, L, 2009) |
"In 14 of the patients with Parkinson's disease, the symptoms were evaluated using conventional scales (UPDS, NYPDS, NWPDS, Schwab and England, and Hoehn and Yahr scale)." | 1.29 | Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease. ( Aceves, J; Flores, G; Ondarza, R; Velasco, F; Velasco, M, 1994) |
"A 64-year-old man was diagnosed to have Parkinson's disease when aged 42 years and since then has been treated with levodopa and benserazide (up to 875 mg daily)." | 1.29 | [Bromocriptine-induced pleuropneumopathy]. ( Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T, 1994) |
"In patients with Parkinson's disease L-dopa prolonged the silent period after transcranial brain stimulation and after ipsilateral cortical stimulation." | 1.29 | Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. ( Accornero, N; Berardelli, A; Inghilleri, M; Manfredi, M; Priori, A, 1994) |
"Bromocriptine (10mg/day) was the second dopaminergic therapy employed in the present work." | 1.28 | [L-dopa, biperiden and sebum excretion in Parkinson disease]. ( Villares, JC, 1989) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 35 (76.09) | 18.7374 |
1990's | 9 (19.57) | 18.2507 |
2000's | 2 (4.35) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gjerden, P | 1 |
Bramness, JG | 1 |
Slørdal, L | 1 |
GERSTENBRAND, F | 1 |
TSCHABITSCHER, H | 1 |
STEINBRECHER, W | 1 |
DRUEN, MA | 1 |
TIMBERLAKE, WH | 1 |
SCHWAB, RS | 1 |
ENGLAND, AC | 1 |
GILLHESPY, RO | 1 |
MUSTARD, DM | 1 |
ROSEN, A | 1 |
BROSCH, H | 1 |
DI CRISTO, G | 1 |
PIRO, S | 1 |
SCARPELLINO, F | 1 |
LERNER, PF | 1 |
O'DOHERTY, DS | 1 |
EDWARDS, CE | 1 |
Aebert, K | 1 |
Puntoni, U | 1 |
Kehr, W | 1 |
Pavoncello, S | 1 |
Di Bianco, V | 1 |
Di Castro, A | 1 |
Caviglia, A | 1 |
Cellitti, M | 1 |
Ondarza, R | 1 |
Velasco, F | 1 |
Velasco, M | 1 |
Aceves, J | 1 |
Flores, G | 1 |
Zappia, M | 1 |
Montesanti, R | 1 |
Colao, R | 1 |
Quattrone, A | 1 |
Linazasoro, G | 1 |
Schmid, PA | 1 |
Suter, T | 1 |
Speich, R | 1 |
Eberli, F | 1 |
Greminger, P | 1 |
Priori, A | 1 |
Berardelli, A | 1 |
Inghilleri, M | 1 |
Accornero, N | 1 |
Manfredi, M | 1 |
Nishiyama, K | 1 |
Mizuno, T | 1 |
Sakuta, M | 1 |
Kurisaki, H | 1 |
Shan, DE | 1 |
Kwan, SY | 1 |
Ho, HH | 1 |
Su, MS | 1 |
Schrag, A | 1 |
Schelosky, L | 1 |
Scholz, U | 1 |
Poewe, W | 1 |
Milanov, I | 1 |
Postma, JU | 1 |
Van Tilburg, W | 1 |
Gerlach, J | 2 |
Thorsen, K | 1 |
Schneider, E | 1 |
Jacobi, P | 1 |
Maxion, H | 1 |
Parkenberg, H | 1 |
Carlsson, M | 1 |
Svensson, A | 1 |
Carlsson, A | 1 |
Villares, JC | 1 |
Kurlan, R | 1 |
Como, P | 1 |
Mano, T | 1 |
Birket-Smith, E | 1 |
Kline, NS | 1 |
Mason, BT | 1 |
Winick, L | 1 |
Barolin, GS | 1 |
Rupprecht, A | 1 |
Jurna, I | 2 |
Krieger, H | 1 |
Nell, T | 1 |
Schreyer, I | 1 |
Simpson, GM | 2 |
Beckles, D | 1 |
Isalski, Z | 1 |
Lee, JH | 1 |
Orlov, P | 1 |
Kasparian, G | 1 |
DiMascio, A | 1 |
Cole, JO | 1 |
Sugano, H | 1 |
Takeya, T | 1 |
Strang, RR | 1 |
Boman, K | 1 |
Meurman, T | 1 |
Kurland, AA | 1 |
Dim, BH | 1 |
Olsson, JE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy[NCT02668497] | Phase 2 | 50 participants (Anticipated) | Interventional | 2016-03-31 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for biperiden and Idiopathic Parkinson Disease
Article | Year |
---|---|
[Drug research on norbornan derivatives. 2].
Topics: 1-Propanol; Acids; Alcohols; Amines; Amino Alcohols; Analgesics; Anesthetics, Local; Animals; Anti-I | 1968 |
9 trials available for biperiden and Idiopathic Parkinson Disease
Article | Year |
---|---|
Usefulness of movement time in the assessment of Parkinson's disease.
Topics: Adult; Aged; Biperiden; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement | 1994 |
Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Biperiden; Cholinergic Antagonist | 1999 |
A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor.
Topics: Aged; Antiparkinson Agents; Biperiden; Cross-Over Studies; Electromyography; Female; Humans; Levodop | 2001 |
The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment.
Topics: Adult; Aged; Biperiden; Cheek; Clinical Trials as Topic; Humans; Methyltyrosines; Middle Aged; Mouth | 1976 |
[Neuropsychological investigations on short-time effects of biperiden (Akineton) in Parkinson's Disease (author's transl)].
Topics: Affect; Biperiden; Drug Evaluation; Humans; Motor Skills; Parkinson Disease; Piperidines; Reaction T | 1975 |
Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Biperid | 1974 |
Some methodological considerations in the evaluation of drug-induced extrapyramidal disorders: a study of Ex10-029, a new morphanthridine derivative.
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Biperiden; Chronic Disease; Clinical Trials as | 1972 |
Controlled studies of antiparkinsonism agents in the treatment of drug-induced extrapyramidal sympttoms.
Topics: 1-Propanol; Adult; Biperiden; Clinical Trials as Topic; Handwriting; Humans; Male; Middle Aged; Neur | 1970 |
Clinical evaluation of biperiden in Parkinson's disease.
Topics: Adult; Aged; Arteriosclerosis; Biperiden; Clinical Trials as Topic; Female; Humans; Male; Middle Age | 1967 |
36 other studies available for biperiden and Idiopathic Parkinson Disease
Article | Year |
---|---|
The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Cholinergic Antagoni | 2009 |
[Experiences with the anti-parkinsonian drug akineton].
Topics: Biperiden; Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease | 1958 |
[Akineton psychoses].
Topics: Biperiden; Cardiovascular Agents; Mental Disorders; Muscle Relaxants, Central; Parkinson Disease; Ps | 1958 |
[Experiences with akineton in ambulant neurological practice].
Topics: Biperiden; Cardiovascular Agents; Databases, Genetic; Muscle Relaxants, Central; Parkinson Disease | 1959 |
Biperiden (Akineton) in Parkinsonism.
Topics: Biperiden; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders | 1961 |
The value of biperiden alone and in combination with bamipine in the treatment of Parkinson's disease.
Topics: Anti-Allergic Agents; Biperiden; Histamine H1 Antagonists; Humans; Parasympatholytics; Parkinson Dis | 1963 |
[Drug-induced parkinsonism and its treatment with Akineton].
Topics: Biperiden; Humans; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders; Tranquilizing Agen | 1963 |
[Report on the use of Akineton in reserpineinduced Parkinsonoid states].
Topics: Biperiden; Parasympatholytics; Parkinson Disease; Reserpine | 1963 |
[Akineton in neurologic therapy with special reference to various forms of parkinsonism].
Topics: Biperiden; Humans; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders | 1963 |
Use of biperiden hydrochloride in Parkinson's disease.
Topics: Biperiden; Humans; Parkinson Disease; Trihexyphenidyl | 1960 |
Akineton in the treatment of parkinsonism.
Topics: Biperiden; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders | 1960 |
[What success does L-Dopa have in the treatment of parkinsonian akinesia?].
Topics: Aged; Biperiden; Blood-Brain Barrier; Desipramine; Dihydroxyphenylalanine; Dopa Decarboxylase; Femal | 1967 |
[Use of biperiden in delayed-release form in the treatment of Parkinson's disease and parkinsonian syndromes of various etiologies. Clinical experiments].
Topics: Adult; Aged; Biperiden; Delayed-Action Preparations; Drug Evaluation; Female; Humans; Male; Middle A | 1983 |
[Drug therapy of Parkinson disease and parkinson disease-like symptoms].
Topics: Adenylyl Cyclases; Animals; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Brain; Catechol O-Methy | 1981 |
[Neurological aspects and modern trends in therapy of Parkinson's disease].
Topics: Atropine; Biperiden; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Procyclidine; Trihexyp | 1980 |
Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease.
Topics: Adult; Aged; Biperiden; Carbidopa; Evaluation Studies as Topic; Humans; Levodopa; Middle Aged; Neuro | 1994 |
Anticholinergics and dyskinesia.
Topics: Aged; Biperiden; Carbidopa; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; | 1994 |
[Bromocriptine-induced pleuropneumopathy].
Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson | 1994 |
Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism.
Topics: Adult; Aged; Biperiden; Brain; Electric Stimulation; Evoked Potentials; Female; Humans; Levodopa; Ma | 1994 |
Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination.
Topics: Aged; Biperiden; Blood Glucose; Brain; Cerebral Cortex; Dementia; Energy Metabolism; Female; Humans; | 1993 |
Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy.
Topics: Abdominal Muscles; Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Biperiden; Dose-Re | 1996 |
Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
Topics: Aged; Amantadine; Benztropine; Biperiden; Delirium; Drug Eruptions; Female; Hallucinations; Humans; | 1975 |
The relationship between parkinsonism and tardive dyskinesia.
Topics: Age Factors; Aminobutyrates; Baclofen; Basal Ganglia; Biperiden; Choline; Dopamine; Dyskinesia, Drug | 1977 |
[Treatment of parkinsonism].
Topics: Amantadine; Benztropine; Biperiden; Humans; Levodopa; Orphenadrine; Parkinson Disease; Procyclidine; | 1976 |
Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice.
Topics: Adrenergic alpha-Agonists; Animals; Atropine; Biperiden; Clonidine; Disease Models, Animal; Dizocilp | 1991 |
[L-dopa, biperiden and sebum excretion in Parkinson disease].
Topics: Aged; Aged, 80 and over; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Bromocriptine; Drug Therap | 1989 |
Drug-induced alzheimerism.
Topics: Aged; Alzheimer Disease; Biperiden; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson | 1988 |
[Dyskinesia induced by anticholinergic drugs--electrophysiological analysis].
Topics: Aged; Benztropine; Biperiden; Electromyography; Female; Humans; Male; Middle Aged; Movement Disorder | 1974 |
Abnormal involuntary movements induced by anticholinergic therapy.
Topics: Aged; Biperiden; Dibenzazepines; Female; Humans; Mastication; Middle Aged; Movement Disorders; Orphe | 1974 |
[Acute reversible Parkinson's syndrome in encephalitis].
Topics: Acute Disease; Adult; Biperiden; Brain; Dopamine; Electroencephalography; Electromyography; Female; | 1967 |
Reserpine rigidity in the rat--a model for the analysis of antiparkinson drugs.
Topics: 1-Propanol; Animals; Biperiden; Cerebral Decortication; Electromyography; Methamphetamine; Models, N | 1968 |
Motor disturbance induced by tremorine and oxotremorine.
Topics: Acetylcholine; Amines; Animals; Atropine; Biperiden; Brain; Bridged-Ring Compounds; Chlorpromazine; | 1970 |
Withdrawal of antiparkinson drugs.
Topics: Biperiden; Butyrophenones; Female; Humans; Male; Parasympatholytics; Parkinson Disease; Psychotic Di | 1971 |
Measurement of body movement and its clinical application.
Topics: Adult; Age Factors; Aged; Biperiden; Body Height; Body Weight; Cerebellar Ataxia; Circadian Rhythm; | 1970 |
Investigations on the effect of some drugs on the Parkinsonian rigidity.
Topics: Adult; Atropine; Biperiden; Female; Humans; Injections, Intravenous; Male; Middle Aged; Muscle Contr | 1970 |
The effectiveness of parenteral administration of fluphenazine decanoate in the treatment of chronic schizophrenics.
Topics: Administration, Oral; Adult; Biperiden; Chronic Disease; Female; Fluphenazine; Humans; Infusions, Pa | 1970 |